Post-test: Nonmelanoma Skin Cancer for Primary Care

News
Article

Find out what you've learned after reading this month's Special Report articles on nonmelanoma lesions you may see in primary care practice.

 

Question 1:


Click on links below for all sections of this Special Report, Non-melanoma Skin Cancer: A Primer for Primary Care

Part 1: Introduction and Pre-test

Part 2: A Pearly-pink Lesion on a 68-year-old Woman's Face

Part 3: Three Suspicious Lesions on an Elderly Woman's Face

Part 4: Actinic Keratosis and Squamous Cell Carcinoma: Photodamage in Progress

Part 5: A Painless, Rapidly-growing Nodule in a 74-year-old Woman

 

Related Content
Astrid Gast/AdobeStock

Elderly Atopic Dermatitis Cases Up 85% in the US Since 1990, New Study Shows

Sydney Jennings
April 23rd 2025
Article

New data also demonstrated mixed sex disparities in elderly atopic dermatitis prevalence.

Global Burden of Atopic Dermatitis in Older Adults Underestimated and Expected to Rise Substantially by 2050 / image credit ©Astrid Gast/stock.adobe.com

Global Burden of Atopic Dermatitis in Older Adults Underestimated and Expected to Rise Substantially by 2050

Grace Halsey
April 21st 2025
Article

The global prevalence of AD in older adults increased by 107% between 1990 and 2021, with a greater burden among women and in high sociodemographic regions.

FDA Approves Dupilumab for Chronic Spontaneous Urticaria Uncontrolled by Antihistamines

FDA Approves Dupilumab for Chronic Spontaneous Urticaria Uncontrolled by Antihistamines

Sydney Jennings
April 18th 2025
Article

Dupilumab (Dupixent) is the first new targeted therapy for CSU in over a decade.

Emerging Therapies Show Potential for Hard-to-Treat Chronic Spontaneous Urticaria

Emerging Therapies Show Potential for Hard-to-Treat Chronic Spontaneous Urticaria

Sydney Jennings
April 18th 2025
Article

New data highlight the potential of dupilumab, remibrutinib, and barzolvolimab to expand treatment options for patients with CSU unresponsive to current therapies.

Study Shows High Rate of Eczema Type Overlap: Daily Dose / image credit: ©New Africa/AdobeStock

Study Shows High Rate of Eczema Type Overlap: Daily Dose

Sydney Jennings
April 11th 2025
Article

Your daily dose of the clinical news you may have missed.

Alphyn Biologics Initiates Phase 2b Trial of Botanical Drug for Atopic Dermatitis / image credit ©Alphyn Biologics

Alphyn Biologics Initiates Phase 2b Trial of Botanical Drug for Atopic Dermatitis

Grace Halsey
April 8th 2025
Article

The investigational botanical zabalafin hydrogel has shown antipruritic, antibacterial, and anti-inflammatory properties, addressing the multifactorial nature of AD.

© 2025 MJH Life Sciences

All rights reserved.